STENTYS : Expands Its Product Offerings for Treating Heart Attacks
05/14/2012| 12:30pm US/Eastern
Recommend:
Regulatory News:
STENTYS S.A. (Paris: STNT)(STNT.PA),
a medical technology company commercializing the world's first
and only Self-Apposing® Stent to treat Acute Myocardial
Infarction (AMI), announced today that it is launching a
thrombectomy device (aspiration catheter) called STENTYS AC.
Heart attacks are caused by the occlusion of a coronary artery due to
clot formation. The European Society of Cardiology (ESC) recommends that
cardiologists try removing as much clot chunks as possible prior to
implanting a stent in order to minimize distal embolization (blockage of
downstream vessels). STENTYS AC is designed to safely recover debris and
can be used in concert with its Self-Apposing devices, STENTYS BMS and
STENTYS DES.
"Coronary thrombectomy devices are a $40 million market and we are very
pleased to offer our customers a device with the best aspiration power
on the market to be used with our breakthrough Self-Apposing Stents for
treating AMI," said Gonzague Issenmann, CEO of STENTYS. "STENTYS
is building a portfolio to offer the complete AMI solution to the cath
lab."
About STENTYS
Based in Princeton, N.J., and Paris, STENTYS has developed a new
generation of stents to treat acute myocardial infarction (AMI) and
bifurcation lesions. Founded by Jacques Séguin, M.D., Ph.D. and Gonzague
Issenmann, STENTYS received CE-marking for its flagship products in
2010. Its Self-Apposing stent adapts to the anatomic
changes of arteries in the post-infarction phase and thus prevents the malapposition
problem associated with conventional stents. STENTYS has commenced
marketing activities in several European countries.
This announcement is not an offer for sale of securities in the United
States. The securities referred to herein have not been offered or sold
in the United States and may not be offered or sold in the United States
of America, except pursuant to a registration statement under the U.S.
Securities Act of 1933, as amended (the "Securities Act"), or pursuant
to an exemption from registrations thereunder. This press release is
being issued pursuant to and in accordance with Rule 135c under the
Securities Act.
Ronald Trahan Associates Inc.
Ronald Trahan, APR, President
+1-508-359-4005,
ext. 108
© Business Wire 2012
Recommend :
